14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 116 days ( 0 % )
Last Price $4.15 0 %
High/ Low $4.15 - $4.15 0%
Chg 7 Days N/A $4.15 $4.15
Chg 30 Days N/A $4.15 $4.15
Chg 12 mos -69.33 % $13.53 $4.15
Trend - 3 mos N/A Width: 0 %
Trend - 12 mos -72.05 % Width: 316.22 %
Pred. range - 3 mos N/A - N/A -100.00 % - -100.00 %
Pred. range - 12 mos N/A - $1.29 -100.00 % - -68.90 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short MA avg 12 mos Sell Mar 14, 2022 - 109 days
Long MA avg 12 mos Sell Jul 20, 2022 - 21 days
Short/Long MA avg 12 mos Sell Jul 20, 2022 - 21 days
Pivot Short Sell Aug 16, 2022 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Zafgen

Zafgen Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate is the Beloranib, an injection, which is in Phase III clinical trials for the treatment of obesity and hyperphagia in patients with Prader-Willi syndrome; that has completed Phase II clinical trials to treat hypothalamic injury-associated obesity, including craniopharyn... ZFGN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT